Insider transaction details
Michael Alfieri, Principal Financial Officer at Aldeyra Therapeutics, Inc. (NASDAQ: ALDX), reported that he acquired 5,000 shares of the company’s common stock on March 18, 2026. The shares were purchased at $1.42 apiece, bringing the total consideration for the purchase to $7,100. As a result of the trade, Alfieri directly holds 7,500 shares of Aldeyra Therapeutics.
Market context and recent price action
The purchase occurred after the company’s stock fell 61% over the previous week. At the time of reporting, the shares were trading at $1.83, which represents a 29% increase over Alfieri’s purchase price of $1.42. According to InvestingPro analysis cited by the company’s reporting, the stock appears undervalued at current levels and there are 14 additional ProTips available to subscribers for more detailed analysis of Aldeyra’s financial position and outlook.
Regulatory setback: FDA Complete Response Letter
Aldeyra recently received a Complete Response Letter from the U.S. Food and Drug Administration rejecting the New Drug Application for reproxalap, a candidate therapy for dry eye disease. The FDA’s stated reasons for the rejection were inconsistencies in study results and an absence of substantial evidence from well-controlled investigations to support the drug’s effectiveness.
Analyst reactions
Following the FDA action, H.C. Wainwright downgraded Aldeyra Therapeutics from Buy to Neutral and lowered its price target substantially from $10.00 to $2.00. By contrast, BTIG retained a Buy rating and kept a $9.00 price target despite the regulator’s concerns regarding the reliability of the study results.
Management change
In addition to the regulatory and market developments, Aldeyra announced that its Chief Development Officer, Stephen G. Machatha, Ph.D., will leave the company by March 2026. Dr. Machatha has entered into a transition agreement to assist in handing over his responsibilities through his departure.
Outlook
These developments - the insider purchase, the FDA rejection citing study inconsistencies, divergent analyst views and an imminent senior R&D leadership change - underscore the immediate challenges Aldeyra faces as it seeks to advance its drug pipeline. The combination of regulatory scrutiny and executive transition will be key factors for investors monitoring the company’s next steps.